Metastatic or advanced NSCLC patients with BRAF V600 mutations generally have a poor prognosis and shorter overall survival, with limited effectiveness of standard chemotherapy and immunotherapy regimens (3, 4). This evidence concerns the gene BRAF and non-small cell lung carcinoma.